Supplement Table 1. The Agency for Health Care Research and Quality (AHRQ) statement for cross-sectional study quality assessment

First author	Year	Study design	1	2	3	4	5	6	7	8	9	10	11	Total scores
Temiz [20]	2021	Cross-sectional	1	1	1	1	1	1	1	1	1	1	0	10
Holtmann [21]	2020	Cohort	1	1	1	1	1	1	1	1	1	1	0	10
Li [22]	2020	Cross-sectional	1	1	1	1	1	1	1	1	1	1	0	9
Rafiee [23]	2021	Cohort	1	1	1	1	1	1	1	0	1	1	1	10
Pazir [24]	2021	Cohort	1	1	1	1	1	1	1	1	0	1	1	11
Gul [25]	2021	Cross-sectional	1	1	1	1	1	1	1	1	0	1	0	9
Koç [26]	2021	Cohort	1	1	1	1	1	1	1	1	0	1	1	10
Ma [27]	2021	Cross-sectional	1	1	1	1	1	1	1	1	0	1	0	9
Ruan [13]	2021	Cross-sectional	1	1	1	1	1	1	1	0	1	1	0	9
Erbay [29]	2021	Cross-sectional	1	1	1	1	1	1	1	1	0	1	1	10
Xu [30]	2021	Cross-sectional	1	1	1	1	1	1	1	0	0	1	0	8
Karkin [31]	2021	Cross-sectional	1	1	1	1	1	1	1	1	0	1	0	9
Okçelik [32]	2021	Cross-sectional	1	1	1	1	1	1	0	1	0	1	0	8
Salonia [33]	2021	Cohort	1	1	1	1	1	1	1	1	1	1	0	10
Cinislioglu [35]	2022	Cohort	1	1	1	1	1	1	1	1	0	1	0	10

1: Define the source of information (survey, record review)?
2: List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications?
3: Indicate time period used for identifying patients?
4: Indicate whether or not subjects were consecutive if not population-based?
5: Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants?
6: Describe any assessments undertaken for quality assurance purposes (*e.g.*, test/retest of primary outcome measurements)?
7: Explain any patient exclusions from analysis?
8: Describe how confounding was assessed and/or controlled?
9: If applicable, explain how missing data were handle in the analysis?
10: Summarize patient response rates and completeness of data collection?
11: Clarify what follow-up, if any, was expected and percentage of patients for which incomplete data or follow-up was obtained